MedPath

Idorsia Ltd

Idorsia Ltd logo
πŸ‡¨πŸ‡­Switzerland
Ownership
Subsidiary
Employees
-
Market Cap
$464M
Website
http://www.idorsia.com

A Study to Evaluate ID-085 in People With Mild, Moderate, and Severe Kidney Disease

Phase 1
Completed
Conditions
Renal Impairment
Interventions
First Posted Date
2019-04-12
Last Posted Date
2019-11-22
Lead Sponsor
Idorsia Pharmaceuticals Ltd.
Target Recruit Count
32
Registration Number
NCT03913000
Locations
πŸ‡©πŸ‡ͺ

CRS Clinical Research Services Kiel GmbH, Kiel, Germany

A Clinical Study to Examine the Drug-drug Interactions Between ACT-541468 and Citalopram in Healthy Male and Female Subjects

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: ACT541468 placebo
First Posted Date
2019-04-08
Last Posted Date
2019-10-31
Lead Sponsor
Idorsia Pharmaceuticals Ltd.
Target Recruit Count
24
Registration Number
NCT03907215
Locations
πŸ‡©πŸ‡ͺ

Parexel International GmbH, Berlin, Germany

A Clinical Study to Assess Next-day Driving Performance Following Administration of ACT-541468 in Middle-aged and Elderly Subjects

Phase 1
Completed
Conditions
Healthy
Interventions
First Posted Date
2019-03-27
Last Posted Date
2019-10-31
Lead Sponsor
Idorsia Pharmaceuticals Ltd.
Target Recruit Count
56
Registration Number
NCT03892902
Locations
πŸ‡³πŸ‡±

Centre for Human Drug Research, Leiden, Netherlands

A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Doses of ACT-1004-1239 in Healthy Male Subjects

Phase 1
Completed
Conditions
Healthy
Interventions
Other: Placebo (Food-effect subpart)
Other: Placebo
Drug: ACT-1004-1239 (Food-effect subpart)
First Posted Date
2019-03-11
Last Posted Date
2020-01-10
Lead Sponsor
Idorsia Pharmaceuticals Ltd.
Target Recruit Count
64
Registration Number
NCT03869320
Locations
πŸ‡ΊπŸ‡Έ

Pharmaron CPC, Inc. & Affiliates, Baltimore, Maryland, United States

A Study in Healthy Subjects to Investigate Whether Administration of Lucerastat Can Affect Normal Heart Function

First Posted Date
2019-02-06
Last Posted Date
2019-10-31
Lead Sponsor
Idorsia Pharmaceuticals Ltd.
Target Recruit Count
44
Registration Number
NCT03832452
Locations
πŸ‡³πŸ‡±

QPS Netherlands B.V., Groningen, Netherlands

A Study to Investigate the Effect of Rifampicin on the Uptake and Breakdown of ACT-246475 in Healthy Subjects

Phase 1
Completed
Conditions
Healthy Subject
Interventions
First Posted Date
2019-01-23
Last Posted Date
2025-07-03
Lead Sponsor
Viatris Innovation GmbH
Target Recruit Count
14
Registration Number
NCT03814200
Locations
πŸ‡³πŸ‡±

QPS Netherlands B.V., Groningen, Netherlands

A Clinical Study to Investigate the Food Effect on the Pharmacokinetics of ACT-541468 in Healthy Male Subjects

Phase 1
Completed
Conditions
Healthy
Interventions
First Posted Date
2019-01-10
Last Posted Date
2019-04-12
Lead Sponsor
Idorsia Pharmaceuticals Ltd.
Target Recruit Count
20
Registration Number
NCT03799978
Locations
πŸ‡¨πŸ‡Ώ

CEPHA s.r.o., Pilsen, Czechia

A Study to Investigate the Effects of ACT-541468 on Nighttime Respiratory Function in Patients With Mild to Moderate Obstructive Sleep Apnea

Phase 1
Completed
Conditions
Obstructive Sleep Apnea
Interventions
Drug: Placebo
First Posted Date
2018-12-05
Last Posted Date
2019-12-19
Lead Sponsor
Idorsia Pharmaceuticals Ltd.
Target Recruit Count
28
Registration Number
NCT03765294
Locations
πŸ‡©πŸ‡ͺ

Advanced Sleep Research, Berlin, Germany

Efficacy and Safety of Four Doses of Cenerimod Compared to Placebo in Adult Subjects With Active Systemic Lupus Erythematosus

Phase 2
Completed
Conditions
Systemic Lupus Erythematosus
Interventions
First Posted Date
2018-11-15
Last Posted Date
2023-09-22
Lead Sponsor
Idorsia Pharmaceuticals Ltd.
Target Recruit Count
427
Registration Number
NCT03742037
Locations
πŸ‡ΊπŸ‡Έ

Pinnacle Research Group, Anniston, Alabama, United States

πŸ‡ΊπŸ‡Έ

University of California San Diego, La Jolla, California, United States

πŸ‡ΊπŸ‡Έ

Valerius Medical Group and Research Center, Los Alamitos, California, United States

and more 145 locations

A Study to Evaluate the Long-term Safety and Tolerability of Lucerastat in Adult Subjects With Fabry Disease

Phase 3
Active, not recruiting
Conditions
Fabry Disease
Interventions
First Posted Date
2018-11-09
Last Posted Date
2025-06-25
Lead Sponsor
Idorsia Pharmaceuticals Ltd.
Target Recruit Count
107
Registration Number
NCT03737214
Locations
πŸ‡ΊπŸ‡Έ

University of Alabama at Birmingham - Nephrology Research Clinic, Birmingham, Alabama, United States

πŸ‡ΊπŸ‡Έ

University of California Irvine, Irvine, California, United States

πŸ‡ΊπŸ‡Έ

UCSF Benioff Children's Hospital Oakland, Oakland, California, United States

and more 39 locations
Β© Copyright 2025. All Rights Reserved by MedPath